Is Vir Biotechnology, Inc. overvalued or undervalued?

As of 4 May 2023, the valuation grade for Vir Biotechnology, Inc. has moved from expensive to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued based on its current metrics, particularly given its negative P/E ratio and a Price to Book Value of 0.72, which suggests that the stock is trading below its book value. Additionally, the EV to EBITDA ratio stands at 0.23, further reinforcing the notion of overvaluation in comparison to its peers.
In the peer comparison, Maravai Lifesciences Holdings, Inc. has a significantly higher EV to EBITDA ratio of -15.5085, while Zentalis Pharmaceuticals, Inc. shows a more favorable EV to EBITDA of 1.0769, indicating that Vir Biotechnology is lagging behind its competitors. The company's recent stock performance has been disappointing, with a year-to-date return of -29.43% compared to the S&P 500's 12.22%, and a staggering -84.17% return over the past five years, which underscores its struggles in the market.